Australia Adult Vaccines Market Overview, 2031

According to the research report, "Australia Adult Vaccines Overview, 2031," published by Bonafide Research, the Australia Adult Vaccines is anticipated to grow at more than 7.25% CAGR from 2026 to 2031.
Australia’s adult vaccines market is experiencing consistent growth, supported by strong government immunization initiatives, rising preventive healthcare awareness, and advancements in vaccine technologies. As one of the most developed healthcare systems in the Asia-Pacific region, Australia has established itself as a leading market for adult immunization programs, focusing on disease prevention, public health protection, and improved healthcare outcomes. Increasing concerns regarding infectious diseases, a rapidly aging population, and ongoing vaccination campaigns are driving demand for adult vaccines across the country. Adult vaccination in Australia plays a vital role in reducing the burden of diseases such as influenza, pneumococcal infections, shingles, hepatitis, HPV, and COVID-19. Vaccination programs help lower hospitalization rates, reduce healthcare costs, and protect vulnerable populations, particularly elderly individuals and patients with chronic conditions. Australia’s healthcare ecosystem strongly emphasizes preventive care, encouraging higher vaccine adoption through government-funded awareness campaigns and subsidized immunization programs.

Historically, Australia’s vaccine sector evolved from depending heavily on imported vaccines to developing a robust domestic manufacturing and research ecosystem. Public-private collaborations and investments in biotechnology have strengthened local vaccine production capabilities, particularly through companies such as CSL Limited’s Seqirus division. The market now includes a broad portfolio of vaccine technologies, including mRNA vaccines, subunit vaccines, live attenuated vaccines, inactivated vaccines, and viral vector-based immunizations. Technological advancements such as AI-driven clinical research, digital immunization tracking systems, and advanced cold-chain logistics are further improving vaccine accessibility and efficiency across Australia. Government policies continue to significantly influence market growth. Programs such as the National Immunisation Program (NIP) and the Pharmaceutical Benefits Scheme (PBS) provide subsidized or free vaccines for eligible adults, ensuring widespread access to essential immunizations. These initiatives have contributed to Australia’s high vaccination coverage rates and strong public confidence in healthcare systems. However, the market still faces challenges including vaccine hesitancy, high research and development costs, and logistical barriers in remote and rural regions.

The competitive landscape of the Australian adult vaccines market is dominated by major global pharmaceutical companies including Pfizer, Moderna, GlaxoSmithKline (GSK), and Sanofi, alongside strong domestic manufacturers such as CSL Seqirus. These companies compete through innovation, product efficacy, advanced vaccine technologies, and strategic collaborations with healthcare providers and government agencies. CSL Seqirus maintains a particularly strong position in the influenza vaccine segment, producing vaccines tailored specifically for the Southern Hemisphere’s seasonal requirements. Global pharmaceutical firms are driving innovation in advanced vaccine technologies, particularly mRNA-based vaccines for COVID-19 and future infectious disease prevention. Their business models often involve partnerships with governments, healthcare institutions, and pharmacies, while local manufacturers focus on balancing domestic supply, exports, and collaborative research initiatives. Vaccine pricing in Australia varies depending on the type and complexity of the vaccine, with standard seasonal influenza vaccines generally ranging between AUD 20 and AUD 40, while specialized vaccines such as shingles and HPV vaccines may cost between AUD 150 and AUD 200 per dose.

Market trends indicate rising demand for booster doses, combination vaccines, and environmentally sustainable packaging solutions. Digital healthcare integration is also improving vaccine monitoring and patient engagement through electronic health records and mobile vaccine tracking applications. Opportunities remain strong in expanding adult vaccination coverage among aging populations, rural communities, and high-risk groups. Additionally, the adoption of AI-driven research platforms is accelerating vaccine development timelines and supporting innovation within Australia’s biotechnology sector. By type, the Australian adult vaccines market is segmented into monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent vaccines provide targeted immunity against specific pathogens and are commonly used for diseases such as hepatitis B and selected meningococcal infections. These vaccines offer highly focused immune responses and are often used in outbreak control and high-risk patient groups. Their lower cost and inclusion under government-funded programs make them accessible across broader population segments.

Multivalent conjugate vaccines, in contrast, provide protection against multiple strains or pathogens within a single dose. Vaccines targeting pneumococcal diseases and meningococcal infections are key examples within this category. These vaccines are increasingly preferred due to their convenience, broader protection, and ability to reduce the number of required injections. Demand for multivalent vaccines is growing rapidly among older adults and immunocompromised individuals, particularly as awareness regarding preventive healthcare continues to increase across Australia. The market can also be segmented by disease category, including varicella, human papillomavirus (HPV), measles, mumps and rubella (MMR), pneumococcal disease, influenza, hepatitis, shingles, and others. The HPV vaccine remains one of Australia’s most successful public health initiatives, contributing significantly to the reduction of cervical cancer and other HPV-related diseases. Australia is recognized globally for its high HPV vaccination coverage and effective awareness programs.



Pneumococcal vaccines are witnessing strong demand due to Australia’s aging demographic profile and increasing prevalence of respiratory diseases. These vaccines help prevent pneumonia, bloodstream infections, and meningitis, particularly among elderly individuals and patients with underlying medical conditions. Seasonal influenza vaccines also remain highly adopted, supported by annual vaccination campaigns and domestic production capabilities led by CSL Seqirus. The MMR and varicella vaccine segments continue to support Australia’s long-term disease prevention strategy by maintaining herd immunity and minimizing outbreaks of highly contagious infections. Additionally, vaccines for hepatitis A and B, shingles, and COVID-19 contribute significantly to public health management and healthcare cost reduction. Australia’s adult vaccines market continues to strengthen its position within the Asia-Pacific healthcare industry through innovation, government support, advanced healthcare infrastructure, and strong public trust in vaccination programs. While countries such as India and China dominate vaccine manufacturing volumes globally, Australia differentiates itself through premium healthcare delivery, policy-driven immunization coverage, advanced biotechnology capabilities, and high standards of vaccine accessibility and safety.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Australia Adult Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top-profiled companies
• Strategic recommendation

By Types
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

By Disease
• Varicella
• Human Papilloma Virus
• Measles
• Mumps & Rubella
• Pneumococcal Disease
• Others